SecBot SecBot
SECBOTREPLAY Home › Report › AGEN

AGEN · Agenus reported Q2 2026 total revenue of $34.5M (up 34% YoY from…

AGENUS INC · 8-K filed Aug 6, 2026 at 07:52 ET

At the news

NEUTRALIMPACT 5/10

8-K filed Aug 6, 2026 at 07:52 ET

Agenus reported Q2 2026 total revenue of $34.5M (up 34% YoY from $25.7M), driven by $6.4M in pre-commercial BOT+BAL product revenue and $28.1M in non-cash royalty revenue. The company highlighted its oversubscribed $85M private placement to fund the Phase 3 ROBBIN trial, but also disclosed the termination of the BATTMAN Phase 3 study due to funding prioritization. The filing is neutral as the revenue beat is largely non-cash royalty revenue, and the strategic pivot to ROBBIN comes at the cost of the BATTMAN trial, creating offsetting signals for a pre-revenue biotech.

  • Total revenue for Q2 2026 was $34.5M, up from $25.7M in Q2 2025.
  • Pre-commercial BOT+BAL product revenue was $6.4M in Q2 2026, up from $4.6M in Q1 2026.
  • Non-cash royalty revenue was $28.1M in Q2 2026, up from $24.8M in Q2 2025.
  • Agenus completed an oversubscribed $85M private placement in July 2026 to support the ROBBIN trial.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access